AAV Vector Resource
Ocular AAV serotype selection should be treated as a coordinated design decision that matches capsid tropism with the target cell, promoter, delivery route, species, and disease model. Photoreceptors, retinal pigment epithelial cells, retinal ganglion cells, and Müller glia occupy different retinal layers, so tissue- and cell-specific AAV targeting and promoter selection should be evaluated alongside AAV vector design. This approach improves retinal targeting, expression specificity, and the interpretability of vision disorder gene therapy studies.
Direct Answer
The eye is small but cell-rich. Rod and cone photoreceptors, retinal ganglion cells, bipolar, amacrine and horizontal cells, Müller glia, and retinal pigment epithelium each sit at a different depth and need a different expression strategy.
Promoters are not "absolutely specific"—their expression range shifts with species, developmental stage, and delivery method. Studies demanding high specificity should combine literature evidence with experimental validation.
The key principle: ocular AAV is a combination of capsid, promoter, and delivery route—not a serotype chosen in isolation.
For rod or cone disease models, distinguish which photoreceptor population needs expression and whether the surviving cells remain accessible. Compare reporter coverage and signal intensity across retinal regions, then check expression in neighboring RPE and inner-retinal cells.
RPE-directed studies need a cassette that expresses in pigment epithelial cells without relying on a capsid result alone for specificity. Quantify the area of RPE expression and assess photoreceptor spillover after the planned subretinal delivery.
RGC targeting depends on access from the vitreous, penetration of the inner limiting membrane, and expression control within the ganglion cell layer. Validate reporter-positive RGCs with cell markers and compare optic nerve or neighboring inner-retinal signal.
Müller glia span the retinal thickness, but reaching these cells and restricting expression to them are different problems. Confirm co-labeling with Müller markers and inspect photoreceptors, RPE, and other glia for unintended expression.
Selection Mapping
Treat the table as a starting map for a capsid–promoter–route combination, not a fixed ranking of serotypes. For each candidate, record the species, dose, injection site, and sampling time, then score target-cell coverage and off-target expression with a matched reporter.
| Target Cell | Representative Promoter | Retinal Layer | Key Caveat |
|---|---|---|---|
| Photoreceptors | Rod/cone-specific | Outer retina | Subretinal exposure favors outer-retinal access; quantify rods and cones separately and record the treated retinal area |
| RPE | RPE-specific | Outer retina | Confirm coverage within the subretinal bleb and check expression outside the RPE |
| Retinal ganglion cells | Inner-retina elements | Inner retina | The inner limiting membrane can restrict access; measure RGC labeling and inner-retinal off-target signal |
| Müller glia | Glial-specific | Full thickness | Confirm Müller-marker co-labeling and compare signal in adjacent neuronal and glial populations |
| Bipolar / amacrine | Interneuron elements | Inner nuclear layer | Use cell markers and layer-resolved imaging to establish which interneurons actually express the reporter |
For cell-type-restricted expression, explore specific promoter-driven AAV targeting and tissue/cell-specific AAV vector services.
Design Logic
Working from the disease goal outward—rather than from the serotype inward—keeps each variable aligned with the next.
Define the disease mechanism and the endpoint: gene replacement, expression mapping, or functional rescue. This determines the cells and retinal region that need exposure.
Identify the disease-relevant cell population and its distribution in the model. Record remaining target-cell numbers when degeneration may limit the measurable response.
Choose a promoter for the desired cell class and expression level, then confirm its size fits the cassette. Test specificity with a reporter in the species and disease stage under study.
Shortlist capsids with evidence for the target layer and intended route. Compare them head to head at matched genome dose rather than treating published tropism as a universal ranking.
Select the route that can expose the target layer and define the expected coverage area. Record injection site, volume, and timing so distribution can be interpreted alongside expression.
Key Variables
Several interacting variables determine whether your AAV reaches and labels the right retinal cells. Controlling them turns a theoretical vector into a reproducible result.
Compare a cell-enriched promoter with an appropriate broad-expression control when specificity matters. Score both the fraction of target cells expressing the reporter and signal in neighboring cell types, because apparent specificity may change with dose and sampling time.
Capsid performance reflects both entry into the eye-facing surface and movement through retinal barriers. Test candidates by the same route and dose, then quantify target-cell coverage across retinal regions rather than relying on a single image.
Intravitreal dosing exposes the retinal surface and often favors inner-retinal targets, while subretinal dosing places vector next to photoreceptors and RPE. Compare route-specific coverage, injection volume, and procedural effects before selecting a lead.
Include both ITRs, promoter, transgene, regulatory elements, and poly(A) sequence in the genome-size plan. A reporter or tag that fits in a pilot cassette may have to be removed from the final construct to preserve the intended design.
scAAV can shorten the time to expression for a compact reporter or payload, but its usable insert capacity is substantially smaller. Compare onset against cassette size and required expression duration before choosing it over single-stranded AAV.
Retinal anatomy, barriers, and promoter activity can alter the outcome across species and disease states. Reconfirm the lead capsid–promoter–route combination in the model closest to the next study rather than assuming mouse coverage predicts larger-eye performance.
Delivery Routes
Choose the administration route around the target layer, intended coverage area, and the tolerance of the disease model to the procedure. The same capsid can produce a different expression pattern when the vector enters from the vitreous instead of the subretinal space.
For inner-retina targets: the vitreous route exposes the retinal surface without creating a subretinal bleb. The inner limiting membrane can limit penetration, so quantify RGC and other inner-retinal expression and check whether the selected capsid reaches deeper layers at the proposed dose.
For outer-retina targets: this route places vector next to photoreceptors and RPE and is used in LCA-related gene replacement. Expression is shaped by the location and extent of the bleb; map treated area and distinguish local coverage from whole-retina efficacy.
Consider the indication: retinitis pigmentosa, AMD, and achromatopsia involve different cell populations and retinal regions. Specify the target cell, surviving tissue, and desired coverage first, then weigh a route-specific reporter result against the planned functional endpoint.
From Question to Evidence
Creative Biolabs can design, construct, and package the AAV that matches your ocular target, from capsid selection through production and titration.
Define the retinal cell population, intended expression profile, and injection route before choosing a promoter and capsid. Build a reporter or study-specific cassette that fits AAV capacity, then review expression-element compatibility and off-target risk for photoreceptor, RPE, RGC, or glial work.
Compare engineered or modified capsids with a reference vector under the same route, dose, and model conditions. Prioritize variants by target-layer access, cell-resolved reporter expression, and off-target signal, recognizing that promoter choice provides an additional layer of expression control.
Produce and purify the chosen capsid–cassette combination at a concentration suited to the planned ocular dose and administration volume. Review lot identity, genome titer, purity, and formulation before assigning material to intravitreal or subretinal cohorts.
Measure vector genome concentration with a defined qPCR or ddPCR assay and add a relevant transduction readout when functional activity must be compared. Record delivered vg per eye, injection volume, and assay method so dose-response and lot comparisons remain interpretable.
Review available recombinant AAV products when an established capsid and expression cassette match the research question. Confirm promoter, payload, formulation, and available lot-level quality data against the target retinal layer and intended route before use.
Selected Reading
Dalkara D, Byrne LC, Klimczak RR, et al. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med. 2013;5(189):189ra76. https://doi.org/10.1126/scitranslmed.3005708.
Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med. 2008;358(21):2240-2248. https://doi.org/10.1056/NEJMoa0802315.
Boye SE, Boye SL, Lewin AS, Hauswirth WW. A comprehensive review of retinal gene therapy. Mol Ther. 2013;21(3):509-519. https://doi.org/10.1038/mt.2012.280.
FAQ
Tell us about your project, and our experts will get back to you with a customized quote and proposal.
